response, Applicants have amended the specification on pages 12, 13, 14, 25 and 26 to recite the appropriate SEQ ID NO tags for the recited sequences.

Applicants note that, contrary to the Examiner's assertion, no nucleotide or amino acid sequence is recited on page 5. Moreover, only sequences containing D amino acids are recited on page 19, line 34 to page 20, line 21. As is stated in 37 C.F.R. § 1.821(a)(2), "Those amino acid sequences containing D-amino acids are not intended to be embraced by this definition." Thus, the specification has not been amended to recite any SEQ ID NO tag for any of the D-amino acid sequences listed on pages 19 and 20.

Applicants note that since the Sequence Listing submitted on April 20, 2001 is correct and in no need of amendment, no substitute Sequence Listing is submitted.

CONCLUSION

Applicants respectfully request that the above-made amendments and remarks be entered and made of record in the file history of the present application.

Applicants respectfully request that the Examiner call the undersigned at 212-790-2129 if any questions or issues remain.

Respectfully submitted,

Date September 24, 2002

29,258
Thomas E. Friebel (Reg. No.)

By:

40,203
William Thomann (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036

Enclosures

EXHIBIT A

Serial No.: 09/206,786
Filed: December 7, 1998
Attorney Docket No.: 8666-007

MARKED-UP VERSION OF THE SPECIFICATION
UNDERLINED TEXT IS ADDED AND [BRACKETED TEXT] IS DELETED

Please amend the following paragraphs to recite as follows:

Amend the paragraph beginning on page 12, line 1 to recite as follows:

In the peptides of the invention, the amino acids corresponding to CD4 amino acid residues 317-323 (SEQ ID NO:5) may be substituted as follows:

Amend the paragraph beginning on page 13, line 4 to recite as follows:

In the peptides of the invention, the amino acids corresponding to CD4 amino acid residues 346-353 (SEQ ID NO:6) may be substituted as follows:

Amend the paragraph beginning on page 14, line 20 to recite as follows:

Thus, as set forth above, in one embodiment, the core sequence from N-terminal to C-terminal is Asn-Ser-Asn-Gln-Ile (NSNQI) (SEQ ID NO:1) and in a second embodiment the core sequence is Ser-Asn-Gln (SNQ). Each amino acid in the core sequences is an L-amino acid. Alternatively, a cyclic synthetic peptide of the present invention can have a "core" sequence which is the reverse of one of the above-noted core sequences, i.e., from N-terminal to C-terminal, IQNSN (SEQ ID NO:41) and QNS. When the core sequence is reversed, each amino acid of the core sequence is a D-amino acid.

Amend the paragraph beginning on page 25, line 23 to recite as follows:

Example 1. Synthesis and Characterization of a C-C' loop Cyclic Heptapeptide: CNSNQIC (SEQ ID NO:45)

The peptide CNSNQIC (SEQ ID NO:45) was synthesized using conventional methods of peptide synthesis. Peptides were synthesized on an Applied Biosystem (Foster City, CA) 430A fully automated peptide synthesizer according to methods of Jameson et al., 1988, Science 240:1335. The peptides containing internal cysteine residues were refolded

and oxidized by dissolving them at 100 μg/ml in 0.1 M NH_4HCO_3 and stirring overnight exposed to air at 23 °C. The peptides show greater than 95% intramolecular disulfide bonding at the end of this procedure as monitored by Ellmans reagents, HPLC analysis and gel filtration. Peptides were lyophilized, resuspended in complete medium and filtered through a 0.22 μ filter prior to use in biological assays.

Amend the paragraph beginning on page 26, line 19 to recite as follows:

Example 2. Synthesis of the peptide: YCNSNQIC (SEQ ID NO:53)

The peptide YCNSNQIC (SEQ ID NO:53) was synthesized and tested *in vitro* in human and murine MLR assay and, *in vivo*, in an EAE protocol. The peptide was found to have inhibitory activity comparable to the cyclic peptide CNSNQIC (SEQ ID NO:45).